BioSpace News Archive

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, announced updates from their rare endocrine disease portfolio with two late-breaking poster presentations and one oral presentation during the Endocrine Society’s ENDO 2024 Meeting that was held June 1-4, 2024, in Boston, Massachusetts.

BrainStorm Cell Therapeutics Inc. is focused on developing autologous mesenchymal stem cell therapies for the treatment of neurodegenerative diseases – BCLI’s primary target is the fatal amyotrophic lateral sclerosis.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024.

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”) - Further to the Company’s news release of June 6, 2024, the Company is pleased to announce that...

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”) is providing an update with respect to the Management Cease Trade Order (“MCTO”) issued by the...

Toronto, Ontario--(Newsfile Corp. - June 14, 2024) - Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) is pleased to announce that it has entered into a non-binding Letter of Intent (the “LOI”) on June 13, 2024, to acquire 100% of the issued and...

MINNEAPOLIS, June 12, 2024 -- Visura Technologies, Inc., a privately owned medical device company based in Minneapolis, today announced an initiative for the next innovation in transesophageal echocardiography (TEE) imaging technology – the TEECAD mini.

Researchers at Children’s Hospital of Philadelphia (CHOP) announced the discovery of a novel immune-based biomarker that could pave the way for potential lifesaving early detection of high-grade ovarian cancer (HGOC).